> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDAers Assess Frontline Renal Cancer Treatments
- URL: https://www.fdaweb.com/fdaers-assess-frontline-renal-cancer-treatments/
- Published: 2023-06-06T12:00:00.000Z
- Updated: 2026-09-14T18:36:27.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154627

Staff in CDER and the Oncology Center of Excellence say a pooled analysis showed the frontline immune-oncology/tyrosine kinase inhibitor (IO/TKI) combination therapy benefit was greater in the intermediate/poor-risk group than the favorable risk group. Writing in *European Urology*, the researchers [say](https://www.sciencedirect.com/science/article/abs/pii/S0302283823028750?dgcid=author&ref=fdaweb.com) they pooled four frontline IO/TKI combinations including 3,098 patients with approvals from 2019 to 2021\. All trials used some IO/TKI combination as the treatment option and sunitinib (Pfizer’s Sutent) as the control, the paper says.

The researchers conclude that the overall survival benefit observed with IO/TKI for metastatic renal cell carcinoma has yet to be demonstrated for favorable-risk patients, and longer follow-up is needed.